AI assistant
InnoCare Pharma Limited Interim / Quarterly Report 2025
51193_rns_2025-05-13_02d2f194-1fd8-47e1-99d7-96f630a8c942.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
INNOCARE
诺诚健华
InnoCare Pharma Limited
諾誠健華醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9969)
2025 QUARTERLY REPORT FOR THE FIRST QUARTER
This announcement is made by InnoCare Pharma Limited (the "Company", together with its subsidiaries, the "Group") pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
2025 QUARTERLY REPORT FOR THE FIRST QUARTER
Reference is made to the "InnoCare Pharma Limited 2025 First Quarterly Report" (the "2025 First Quarterly Report") published by the Company on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2025 First Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.
The board (the "Board") of directors (the "Directors") of the Company reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee of the Company, but have not been reviewed by the independent auditors of the Company.
The unaudited financial data in the 2025 First Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People's Republic of China instead of the International Financial Reporting Standards, and are prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.
Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.
By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director
Hong Kong, 13 May 2025
As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.
- 2 -
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
Stock Code: 688428
Ticker Symbol: InnoCare
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
The board of directors and all directors of the Company affirm that this announcement contains no false records or misleading statements or material omissions and that they are responsible for the truthfulness, accuracy, and completeness of its contents in accordance with the laws.
IMPORTANT NOTICE
The board of directors, directors and senior management of the Company undertake that the contents of the quarterly report are true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor.
The person in charge of the Company, person in charge of accounting function and person in charge of the Accounting Department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report.
Whether the first quarterly financial statements have been audited
☐ Yes ☑ No
MANAGEMENT PERFORMANCE REVIEW
The management of InnoCare Pharma Limited ("InnoCare" or the "Company") commented, "The Company is a high-tech innovative biopharmaceutical enterprise driven by outstanding independent research and development capabilities, possessing comprehensive research and development, manufacturing and commercialization abilities. It focuses on areas with significant unmet clinical needs such as oncology and autoimmune diseases, developing drugs with breakthrough potential that are either first-in-class or best-in-class on a global scale.
From January to March 2025, total operating revenue of the Company reached RMB381 million, representing an increase of $129.92\%$ as compared to the same period last year. Meanwhile, the Company
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
has continued to improve its gross profit margin, which has reached 90.5% from January to March 2025, representing an increase of 5.1 percentage points from 85.4% of the same period last year. The high growth in operating revenue and gross profit margin was mainly attributable to continuous increase in sales revenue of our core product orelabrutinib (宜諾凱®) and the upfront payment for the exclusive license agreement between the Company and Prolium Bioscience Inc. ("Prolium"). From January to March 2025, the Company made a net profit of RMB14 million, achieving profit comparing with the same period of last year.
From January to March 2025, sales revenue of the Company's core product, orelabrutinib (宜諾凱®), has continued to increase. It recorded sales revenue of RMB311 million, representing a year-over-year increase of 89.22%. In April 2025, orelabrutinib has been approved for a new indication for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Previously, all three indications for orelabrutinib, including relapsed and refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (r/r CLL/SLL), relapsed and refractory mantle cell lymphoma (MCL) (r/r MCL) and relapsed and refractory marginal zone lymphoma (MZL) (r/r MZL) have been covered in the National Reimbursement Drug List, especially orelabrutinib has been approved as the first and only BTK inhibitor for MZL indication in China. According to the newly issued Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Malignant Lymphoma for 2025, orelabrutinib was included in various recommended regimens, including: listed as a Class I recommended regimen for the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), continued as a Class I recommended regimen for MZL treatment, and listed as a Class II recommended regimen for the first-line treatment of mantle cell lymphoma (MCL).
As of 31 March 2025, the Company held cash and related accounts balance (including cash and bank balances, financial assets held for trading, financial assets in other current assets, non-current assets due within one year and other non-current assets) amounted to approximately RMB7.778 billion. With sufficient cash reserves, the Company will continue to accelerate the development of various pipeline projects in an effort to provide more and better treatment options for patients in China and around the world."
I. KEY FINANCIAL INFORMATION
(I) Key accounting data and financial indicators
Unit: RMB Currency: Renminbi
| Items | The reporting period | Same period of last year | Increase/decrease during the reporting period compared with the same period of last year (%) |
|---|---|---|---|
| Operating revenue | 381,263,139.35 | 165,824,020.34 | 129.92 |
| Among which: revenue from sales | 311,666,494.52 | 164,803,923.62 | 89.11 |
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
| of drugs | |||
|---|---|---|---|
| Net profit attributable to shareholders of the listed company | 17,967,628.89 | -142,403,395.72 | N/A |
| Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses | 1,591,658.29 | -133,949,358.24 | N/A |
| Net cash flows generated from operating activities | 56,524,292.65 | -84,043,543.78 | N/A |
| Basic earnings per share (RMB/share) | 0.01 | -0.08 | N/A |
| Diluted earnings per share (RMB/share) | 0.01 | -0.08 | N/A |
| Weighted average return on equity (%) | 0.27 | -2.01 | N/A |
| Total R&D expenditure | 207,599,189.43 | 177,728,720.87 | 16.81 |
| R&D expenditure as a percentage of operating revenue (%) | 54.45 | 107.18 | Decrease of 52.73 percentage points |
| As at the end of the reporting period | As at the end of the last year | Increase/decrease as at the end of the reporting period compared with the end of last year (%) | |
| Total assets | 9,413,626,277.76 | 9,407,493,740.91 | 0.07 |
| Owners’ equity attributable to shareholders of the listed company | 6,748,973,642.92 | 6,725,301,365.03 | 0.35 |
(II) Non-recurring profits and losses items and amounts
☑ Applicable ☐ Not applicable
Unit: RMB Currency: Renminbi
| Non-recurring profits and losses items | Amount for the reporting period | Description |
|---|---|---|
| Profits and losses on disposal of non-current assets, including the write-off portion of asset impairment provisions that have been made | 3,398.23 | |
| Government grants included in current profits and losses (excluding those closely related to the Company’s normal course of business operations, in compliance with national policies and regulations, and have a continuous impact on the Company’s profit or loss according to established standards) | 3,375,038.61 | |
| Profits and losses arising from changes in fair value of financial assets and financial liabilities held by a | 13,026,264.64 |
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
| non-financial enterprise, and profits and losses arising from disposal of financial assets and financial liabilities, except for effective hedging business related to the Company's normal operations | ||
|---|---|---|
| Other non-operating income and expenses other than the above items | - | |
| Less: Effect on income tax | - | |
| Effect on minority interests (after tax) | 28,730.88 | |
| Total | 16,375,970.60 |
Note: Non-recurring profits and losses items were recognized by the Company in compliance with the requirements of the "Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses" (CSRC Announcement [2023] No. 65).
Reasons should be provided for identifying items not listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses" as non-recurring profit or loss items with significant amounts, as well as for defining the non-recurring profit or loss items set out in the "Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses" as recurring profit or loss items.
☐ Applicable ☑ Not applicable
(III) Changes in key accounting data and financial indicators and the reasons therefor
☑ Applicable ☐ Not applicable
| Item | Percentage change (%) | Main reason |
|---|---|---|
| Operating revenue | 129.92 | Significant increase in operating revenue was due to continuous increase in sales volume of orelabrutinib as well as the recognition of revenue related to the upfront payment for the exclusive license agreement with Prolium |
| Among which: revenue from sales of drugs | 89.11 | |
| Net profit attributable to shareholders of the listed company | N/A | The Company achieved profit of the period, which was primarily due to significant increase in operating |
| Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses | N/A | revenue, including continuous increase in sales volume of orelabrutinib as well as the recognition of revenue related to the upfront payment for the exclusive license agreement with Prolium |
| Basic earnings per share (RMB/share) | N/A | This was primarily due to the achievement of profit in the current period compared with the same period last year, leading to an increase in net profit attributable to shareholders of the listed company |
| Diluted earnings per share (RMB/share) | N/A | This was primarily due to the achievement of profit in the current period compared with the same period last year, leading to an increase in net profit attributable to shareholders of the listed company |
| R&D expenditure as a percentage of operating revenue (%) | Decreased by 52.73 percentage point | This was primarily due to the significant increase in operating revenue for the period |
| Net cash flows generated from operating activities | N/A | The significant increase in cash inflow in the current period compared with the same period last year was mainly due to a higher increase in cash received from sales of goods and the upfront |
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
II. SHAREHOLDER INFORMATION
- As of the end of the reporting period, the total number of issued shares of the Company was 1,762,567,202 shares, of which 1,496,284,235 shares were issued in Hong Kong, representing approximately $84.89\%$ of the total issued shares of the Company. The number of RMB shares issued on the SSE STAR Market was 266,282,967 shares, representing approximately $15.11\%$ of the total issued shares of the Company.
- The Hong Kong register of members of the Company consists of HKSCC NOMINEES LIMITED (HKSCC Nominees Limited) and other registered shareholders, of which HKSCC NOMINEES LIMITED held approximately $99.999\%$ of the Company's Hong Kong shares on behalf of non-registered shareholders, and approximately $0.001\%$ of the Company's Hong Kong shares were held by other registered shareholders.
- Shares held by HKSCC NOMINEES LIMITED are held on behalf of various customers. According to the disclosure information in declaration submitted by shareholders on the Hong Kong Stock Exchange as of the end of the reporting period, the Company displayed in the table below the shares held by HKSCC NOMINEES LIMITED after excluding the shares held by HHLR Fund, L.P. and its persons acting in concert, King Bridge Investments Limited and its persons acting in concert, Sunny View Holdings Limited and the family of Renbin Zhao and Sunland BioMed Ltd and the family of Jisong Cui, respectively.
- As of the end of the reporting period, the shareholdings of the top ten shareholders are listed based on the disclosure information in declaration submitted by the relevant shareholders to the Hong Kong Stock Exchange and the A share register provided by CSDC. The nature of A shareholders is reported in accordance with the categories of holders in the A share register of CSDC.
(I) Total number of ordinary shareholders and the number of preferred shareholders whose voting rights have been restored, and shareholdings of the top ten shareholders
Unit: share
| Total number of ordinary shareholders as at the end of the reporting period | 13,343 | Total number of preferred shareholders whose voting rights have been restored as at the end of the reporting period (if any) | - | ||||
|---|---|---|---|---|---|---|---|
| Shareholdings of the top ten shareholders (excluding lending shares for refinancing) | |||||||
| Name of shareholder | Nature of shareholder | Number of shares held | Percentage of shareholding (%) | Number of restricted shares held | Number of restricted shares (including lending shares for refinancing) | Pledged, marked or frozen | |
| Status of shares | Number of shares | ||||||
| HKSCC NOMINEES LIMITED | Unknown | 856,006,175 | 48.5659 | - | - | Unknown | - |
| HHLR Fund, L.P. and its persons acting in concert | Overseas legal person | 208,671,222 | 11.8391 | - | - | Unknown | - |
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
| King Bridge Investments Limited and its persons acting in concert | Overseas legal person | 158,588,612 | 8.9976 | - | - | Unknown | - |
|---|---|---|---|---|---|---|---|
| Sunny View Holdings Limited and the family of Renbin Zhao | Overseas legal person | 144,717,893 | 8.2106 | - | - | Nil | - |
| Overseas natural person | |||||||
| Sunland BioMed Ltd and the family of Jisong Cui | Overseas legal person | 126,600,282 | 7.1827 | - | - | Nil | - |
| Overseas natural person | |||||||
| Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Securities Investment Fund | Others | 15,213,454 | 0.8631 | - | - | Nil | - |
| China Construction Bank Corporation - Fullgoal Precision Medicine Flexible Allocation Hybrid Securities Investment Fund | Others | 12,582,004 | 0.7138 | - | - | Nil | - |
| China Merchants Bank Co., Ltd. - Xingquan Herun Hybrid Securities Investment Fund | Others | 12,039,154 | 0.6830 | - | - | Nil | - |
| Bank of China Limited - PingAn Healthcare Flexible Allocation Hybrid Securities Investment Fund | Others | 9,406,234 | 0.5337 | - | - | Nil | - |
| Industrial and Commercial Bank of China Limited - Zhong Ou Healthcare Hybrid Securities Investment Fund | Others | 9,067,019 | 0.5144 | - | - | Nil | - |
| Shareholdings of the top ten unrestricted shareholders (excluding lending shares for refinancing) | |||||||
| Name of shareholder | Number of unrestricted outstanding shares held | Type and number of shares | |||||
| Type | Number | ||||||
| HKSCC NOMINEES LIMITED | 856,006,175 | Others | 856,006,175 | ||||
| HHLR Fund, L.P. and its persons acting in concert | 208,671,222 | Others | 208,671,222 | ||||
| King Bridge Investments Limited and its persons acting in concert | 158,588,612 | Others | 158,588,612 | ||||
| Sunny View Holdings Limited and the family Renbin Zhao | 144,717,893 | Others | 144,717,893 | ||||
| Sunland BioMed Ltd and the family of Jisong Cui | 126,600,282 | Others | 126,600,282 |
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
| Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Securities Investment Fund | 15,213,454 | RMB-denominated ordinary shares | 15,213,454 |
|---|---|---|---|
| China Construction Bank Corporation - Fullgoal Precision Medicine Flexible Allocation Hybrid Securities Investment Fund | 12,582,004 | RMB-denominated ordinary shares | 12,582,004 |
| China Merchants Bank Co., Ltd. - Xingquan Herun Hybrid Securities Investment Fund | 12,039,154 | RMB-denominated ordinary shares | 12,039,154 |
| Bank of China Limited – PingAn Healthcare Flexible Allocation Hybrid Securities Investment Fund | 9,406,234 | RMB-denominated ordinary shares | 9,406,234 |
| Industrial and Commercial Bank of China Limited - Zhong Ou Healthcare Hybrid Securities Investment Fund | 9,067,019 | RMB-denominated ordinary shares | 9,067,019 |
| Description of the connected relationships among, or concerted actions taken by the above shareholders | The Company is not aware of whether the above other shareholders have other related relationships or concerted action relationships | ||
| Description of the top ten shareholders and the top ten unrestricted shareholders involved in margin financing and securities lending and refinancing businesses (if any) | Nil |
Involvement of shareholders with shareholdings of more than $5\%$ , top ten shareholders and top ten unrestricted shareholders in lending shares for refinancing businesses
Applicable Not applicable
Changes of top ten shareholders and top ten unrestricted shareholders as compared with the previous period due to lending/returning shares for refinancing
Applicable Not applicable
III. OTHER REMINDERS
Other important information about the operation of the Company during the reporting period to which investors should pay attention
Applicable Not applicable
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Types of audit opinions
☐ Applicable √ Not applicable
(II) Financial statements
Consolidated balance sheet
31 March 2025
Prepared by: InnoCare Pharma Limited
Unit: RMB Currency: Renminbi Audit type: Unaudited
| Items | March 31, 2025 | December 31, 2024 |
|---|---|---|
| Current assets: | ||
| Cash and bank balances | 6,326,896,740.80 | 6,240,825,867.22 |
| Financial assets held for trading | 681,190,697.06 | 759,178,751.34 |
| Accounts receivable | 363,566,458.95 | 351,002,029.47 |
| Receivables financing | 23,755.40 | - |
| Prepayments | 56,065,495.53 | 57,291,586.16 |
| Other receivables | 241,808.66 | 1,962,640.34 |
| Inventories | 97,071,778.41 | 95,576,094.32 |
| Non-current assets due within one year | 53,201,751.42 | - |
| Other current assets | 319,192,683.35 | 314,351,615.36 |
| Total current assets | 7,897,451,169.58 | 7,820,188,584.21 |
| Non-current assets: | ||
| Long-term equity investments | 479,169.42 | 400,224.71 |
| Fixed assets | 599,155,023.23 | 615,870,417.40 |
| Construction in progress | 141,050,581.08 | 138,863,175.88 |
| Right-of-use assets | 56,866,200.55 | 59,539,796.29 |
| Intangible assets | 255,966,660.76 | 258,135,389.48 |
| Goodwill | 3,124,706.56 | 3,124,706.56 |
| Long-term prepaid expenses | 30,413,094.73 | 31,941,423.73 |
| Other non-current assets | 429,119,671.85 | 479,430,022.65 |
| Total non-current assets | 1,516,175,108.18 | 1,587,305,156.70 |
| Total assets | 9,413,626,277.76 | 9,407,493,740.91 |
| Current liabilities: | ||
| Short-term borrowings | 80,056,438.36 | 137,449,996.40 |
| Accounts payable | 165,680,796.30 | 128,362,410.02 |
| Payroll payable | 41,169,332.13 | 62,649,153.97 |
| Taxes payable | 41,873,816.18 | 31,113,378.26 |
| Other payables | 106,869,046.26 | 125,413,532.20 |
| Non-current liabilities due within one year | 95,493,242.86 | 87,954,787.56 |
| Other current liabilities | 476,336,000.00 | 476,336,000.00 |
8 / 12
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
| Total current liabilities | 1,007,478,672.09 | 1,049,279,258.41 |
|---|---|---|
| Non-current liabilities: | ||
| Long-term borrowings | 1,036,400,000.00 | 1,018,700,000.00 |
| Lease liabilities | 25,206,692.47 | 27,440,249.68 |
| Long-term payables | 307,685,799.37 | 303,134,143.93 |
| Deferred income | 270,739,354.94 | 263,004,453.83 |
| Total non-current liabilities | 1,640,031,846.78 | 1,612,278,847.44 |
| Total liabilities | 2,647,510,518.87 | 2,661,558,105.85 |
| Owners’ equity (or shareholders’ equity): | ||
| Paid-in capital (or share capital) | 23,399.72 | 23,399.72 |
| Capital reserve | 12,128,778,642.24 | 12,110,535,925.61 |
| Less: Treasury shares | 9,009,965.68 | 3,097,201.31 |
| Other comprehensive income | 131,367,680.36 | 137,992,983.62 |
| Retained earnings | -5,502,186,113.72 | -5,520,153,742.61 |
| Total equity attributable to owners (or shareholders) of the parent company | 6,748,973,642.92 | 6,725,301,365.03 |
| Minority interests | 17,142,115.97 | 20,634,270.03 |
| Total owners’ equity (or shareholders’ equity) | 6,766,115,758.89 | 6,745,935,635.06 |
| Total liabilities and owners’ equity (or shareholders’ equity) | 9,413,626,277.76 | 9,407,493,740.91 |
Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu Person in charge of the Accounting Department: Yue Tan
Consolidated Statement of Income
January-March 2025
Prepared by: InnoCare Pharma Limited
Unit: RMB Currency: Renminbi Audit type: Unaudited
| Items | First Quarter in 2025 | First Quarter in 2024 |
|---|---|---|
| I. Total operating revenue | 381,263,139.35 | 165,824,020.34 |
| Including: Operating revenue | 381,263,139.35 | 165,824,020.34 |
| II. Total operating costs | 383,940,887.34 | 303,015,436.11 |
| Including: Operating costs | 36,066,440.09 | 24,290,417.68 |
| Taxes and surcharges | 6,989,137.10 | 3,036,877.51 |
| Selling expenses | 114,012,126.98 | 89,533,244.90 |
| Administrative expenses | 42,762,733.27 | 42,408,649.62 |
| R&D expenses | 207,599,189.43 | 177,728,720.87 |
| Finance costs | -23,488,739.53 | -33,982,474.47 |
| Including: Interest expenses | 13,518,113.67 | 5,177,359.39 |
| Interest income | 33,751,558.37 | 47,128,560.55 |
| Add: Other income | 5,912,441.49 | 9,316,072.39 |
| Investment income (loss denoted by | 10,544,273.33 | -1,339,525.49 |
| in the interest of the parent company |
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
| “-”) | ||
|---|---|---|
| Including: Share of profit of associates and joint ventures | 78,944.71 | -1,339,525.49 |
| Gain from changes in fair value (loss denoted by “-”) | 2,560,936.02 | -16,476,486.81 |
| Credit impairment loss (loss denoted by “-”) | 239,188.28 | - |
| Impairment loss of assets (loss denoted by “-”) | -188,438.83 | - |
| Gain from disposal of assets (loss denoted by “-”) | 3,398.23 | - |
| III. Operating profit (loss denoted by “-”) | 16,394,050.53 | -145,691,355.68 |
| Add: Non-operating income | - | 31,000.10 |
| Less: Non-operating expenses | - | - |
| IV. Total profit (total loss denoted by “-”) | 16,394,050.53 | -145,660,355.58 |
| Less: Income tax expenses | 1,918,575.70 | 20.10 |
| V. Net profit (net loss denoted by “-”) | 14,475,474.83 | -145,660,375.68 |
| (I) By continuity of operations | ||
| 1. Net profit from continuing operations (net loss denoted by “-”) | 14,475,474.83 | -145,660,375.68 |
| 2. Net profit from discontinued operations (net loss denoted by “-”) | - | - |
| (II) By attribution of ownership | ||
| 1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”) | 17,967,628.89 | -142,403,395.72 |
| 2. Profit or loss attributable to minority shareholders (net loss denoted by “-”) | -3,492,154.06 | -3,256,979.96 |
| VI. Other comprehensive income, net of tax | -6,625,303.26 | 10,452,098.53 |
| (I) Other comprehensive income attributable to owners of the parent company, net of tax | -6,625,303.26 | 10,452,098.53 |
| 1. Other comprehensive income not to be reclassified to profit or loss | -6,625,303.26 | 10,452,098.53 |
| (1) Translation differences of the financial statements in foreign currency | -6,625,303.26 | 10,452,098.53 |
| VII. Total comprehensive income | 7,850,171.57 | -135,208,277.15 |
| (I) Total comprehensive income attributable to owners of the parent company | 11,342,325.63 | -131,951,297.19 |
| (II) Total comprehensive income attributable to minority shareholders | -3,492,154.06 | -3,256,979.96 |
| VIII. Earnings per share: | ||
| (I) Basic earnings per share (RMB/share) | 0.01 | -0.08 |
10 / 12
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
For business combinations under the same control in the current period, the net profit achieved by the parties consolidated prior to the consolidation was RMB0.00; the net profit achieved by the parties consolidated in the previous period was RMB0.00.
Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu Person in charge of the Accounting Department: Yue Tan
Consolidated Statement of Cash Flows
January-March 2025
Prepared by: InnoCare Pharma Limited
Unit: RMB Currency: Renminbi Audit type: Unaudited
| Items | First Quarter in 2025 | First Quarter in 2024 |
|---|---|---|
| I. Cash flows generated from operating activities: | ||
| Cash receipts from sales of goods and provision of services | 417,205,824.01 | 268,172,063.57 |
| Cash received from other operating activities | 30,398,876.74 | 20,650,437.77 |
| Sub-total of cash inflows from operating activities | 447,604,700.75 | 288,822,501.34 |
| Cash paid for goods and services | 145,285,952.64 | 180,566,928.06 |
| Cash paid to and on behalf of employees | 173,484,298.83 | 157,277,358.24 |
| Cash paid for taxes and levies | 35,333,690.31 | 10,258,771.66 |
| Cash paid for other operating activities | 36,976,466.32 | 24,762,987.16 |
| Sub-total of cash outflows from operating activities | 391,080,408.10 | 372,866,045.12 |
| Net cash flows generated from operating activities | 56,524,292.65 | -84,043,543.78 |
| II. Cash flows generated from investment activities: | ||
| Cash received from the disposal of investments | 1,401,285,200.00 | 1,015,590,381.62 |
| Cash received from investment income | 16,054,993.70 | 28,096,224.65 |
| Sub-total of cash inflows from investment activities | 1,417,340,193.70 | 1,043,686,606.27 |
| Cash paid for acquisition of fixed assets, intangible assets and other long-term assets | 15,058,034.49 | 26,011,755.52 |
| Cash paid for investments | 1,324,058,800.00 | 515,000,000.00 |
InnoCare Pharma Limited 2025 FIRST QUARTERLY REPORT
| Sub-total of cash outflows from investment activities | 1,339,116,834.49 | 541,011,755.52 |
|---|---|---|
| Net cash flows generated from investing activities | 78,223,359.21 | 502,674,850.75 |
| III. Cash flows generated from financing activities: | ||
| Cash received from capital contributions | 303,955.42 | 718,358.35 |
| Cash received from borrowings | 79,200,000.00 | 6,800,000.00 |
| Cash received from other financing activities | 86,420,746.40 | - |
| Sub-total of cash inflows from financing activities | 165,924,701.82 | 7,518,358.35 |
| Cash paid for repayment of debts | 110,920,746.40 | - |
| Cash paid for distribution of dividends or profits or settlement of interest | 8,175,035.27 | 287,534.72 |
| Cash paid for other financing activities | 14,075,083.07 | 14,671,100.35 |
| Sub-total of cash outflows from financing activities | 133,170,864.74 | 14,958,635.07 |
| Net cash flows generated from financing activities | 32,753,837.08 | -7,440,276.72 |
| IV. Effects of changes in exchange rate on cash and cash equivalents | -3,257,880.35 | 2,726,913.06 |
| V. Net increase in cash and cash equivalents | 164,243,608.59 | 413,917,943.31 |
| Add: Balance of cash and cash equivalents at the beginning of the period | 4,679,466,477.13 | 4,202,563,804.93 |
| VI. Balance of cash and cash equivalents at the end of the period | 4,843,710,085.72 | 4,616,481,748.24 |
Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu
Person in charge of the Accounting Department: Yue Tan
(III) Adjustment of the financial statements for the beginning of 2025 when the Company implements the new accounting standards or interpretation of standards for the first time
☐ Applicable √ Not applicable
The announcement is hereby made.
Board of directors of InnoCare Pharma Limited
13 May 2025
12 / 12